Brought to you by 
AbbVie pays for option to acquire Alvine equity or its celiac disease compound
18 Dec 2015
Executive Summary
In an effort to strengthen its existing gastroenterology pipeline, Abbott Laboratories Inc.’s spin off AbbVie Inc. has paid $70mm up front for the exclusive option to acquire either equity in Alvine Pharmaceuticals Inc. (developing therapies autoimmune and inflammatory diseases) or its Phase IIa oral celiac disease compound ALV003 and related assets.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AbbVie pays for option to acquire Alvine equity or its celiac disease compound
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice